MARK LASSISE: Open Payments
NPI 1023002508 · MASON CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$998 in 50 payments from 12 companies in 2025. Trend: 2023 $929 · 2024 $955 · 2025 $998
Food & beverage: $998
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $263 |
| ABBVIE INC. | 11 | $194 |
| Teva Pharmaceuticals USA, Inc. | 6 | $143 |
| Neurocrine BioSciences, Inc. | 6 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Janssen Pharmaceuticals, Inc | 3 | $53 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
| Lundbeck LLC | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: REXULTI, VRAYLAR, INGREZZA, UZEDY, AUSTEDO XR, CAPLYTA, Auvelity, ABILIFY ASIMTUFII.
Industry payments across IA — which companies pay providers there.
